# Kebilidi (eladocagene exuparvovec-tneq)

**July 6, 2026**

Kebilidi (eladocagene exuparvovec-tneq) is an adeno-associated virus (AAV) vector-based gene therapy indicated to treat adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.

## Authorization requirements

- Prior authorization is required for Kebilidi (eladocagene exuparvovec-tneq).
- The prior authorization request for a single dose of intraputaminal infusion of Kebilidi may be approved for a duration of 12 months for patients who meet the following requirements:

    a. The patient is 16 months or older.
    b. The patient has a confirmed diagnosis of AADC deficiency (diagnosis code: E70.81).
    c. The patient has presence of biallelic mutations in the *DDC* gene identified by molecular genetic testing.
    d. Documentation of skull assessment confirming the patient has achieved skull maturity by neuroimaging, necessary for stereotactic neurosurgical administration of Kebilidi therapy.
    e. The patient has not previously received Kebilidi infusion for AADC deficiency.

- Eladocagene exuparvovec-tneq (Kebilidi) (procedure code J3590) is limited to once per lifetime.
- Monitoring parameters:
    a. Monitor for post-procedural complications, which may include events of respiratory and cardiac arrest after Kebilidi administration.
    b. Monitor for additional procedure related adverse events, such as cerebrospinal fluid leak, intracranial bleeding, neuroinflammation, acute infarction, and infection.
    c. Monitor for signs of dyskinesia or involuntary movements of face, arm, leg or the entire body (fidgeting, writhing, wriggling, head bobbing or body swaying) after administration of Kebilidi.